-
Categories
-
Pharmaceutical Intermediates
-
Active Pharmaceutical Ingredients
-
Food Additives
- Industrial Coatings
- Agrochemicals
- Dyes and Pigments
- Surfactant
- Flavors and Fragrances
- Chemical Reagents
- Catalyst and Auxiliary
- Natural Products
- Inorganic Chemistry
-
Organic Chemistry
-
Biochemical Engineering
- Analytical Chemistry
-
Cosmetic Ingredient
- Water Treatment Chemical
-
Pharmaceutical Intermediates
Promotion
ECHEMI Mall
Wholesale
Weekly Price
Exhibition
News
-
Trade Service
Encouraged by favorable policies and the growth of market demand under the normalization of the epidemic, the terminal pediatric proprietary Chinese medicine market in China's public medical institutions continued to recover, with sales exceeding RMB4.
6 billion in the first half of 2022, and is expected to return to the pre-epidemic level
throughout the year.
Pediatric cold medicine, pediatric cough and expectorant medicine are the main forces, Jichuan ranks first, and Kang Yuan climbs rapidly; 13 exclusive proprietary Chinese medicines seized the top 20 products, many of which were recommended for children's treatment programs in the "Guidelines for Home Medicine Intervention for Patients with New Coronavirus Infection", and 8 of the top 20 brands increased by more than 10%.
According to incomplete statistics, there are currently 30 new pediatric proprietary Chinese medicine drugs in the clinical application stage and above, involving Huluwa, Jichuan, Jianmin, Yiling and other enterprises
.
01.
The pediatric proprietary Chinese medicine market continues to warm up!
In
recent years, driven by the dual promotion of national favorable policies and market demand growth, the scale of the domestic pediatric drug market has grown rapidly
.
Proprietary Chinese medicines have the characteristics of fewer side effects and milder medicinal properties, and are widely
used in children.
According to data from Minai.
com, before 2020, the market size of pediatric proprietary Chinese medicines in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) has increased year after year, with double-digit
growth rates.
Affected by the epidemic in 2020, the pediatric proprietary Chinese medicine market has declined, and after the normalization of the epidemic in 2021, it began to warm up sharply, with a year-on-year increase of 47.
54%, and the sales scale in the first half of 2022 exceeded 4.
6 billion yuan, an increase of 6.
12% over the same period last year, and it is expected to return to the pre-epidemic level
in 2022.
From the perspective of treatment categories, pediatric proprietary Chinese medicines covered 7 treatment subcategories, focusing on pediatric cold medicine and pediatric cough expectorant medicine, accounting for 43% and 38%
of sales respectively.
Due to the low immunity of children, colds and coughs are more common in daily life, and the demand for medication is relatively large
.
6 billion in the first half of 2022, and is expected to return to the pre-epidemic level
throughout the year.
Pediatric cold medicine, pediatric cough and expectorant medicine are the main forces, Jichuan ranks first, and Kang Yuan climbs rapidly; 13 exclusive proprietary Chinese medicines seized the top 20 products, many of which were recommended for children's treatment programs in the "Guidelines for Home Medicine Intervention for Patients with New Coronavirus Infection", and 8 of the top 20 brands increased by more than 10%.
According to incomplete statistics, there are currently 30 new pediatric proprietary Chinese medicine drugs in the clinical application stage and above, involving Huluwa, Jichuan, Jianmin, Yiling and other enterprises
.
01.
The pediatric proprietary Chinese medicine market continues to warm up!
In
recent years, driven by the dual promotion of national favorable policies and market demand growth, the scale of the domestic pediatric drug market has grown rapidly
.
Proprietary Chinese medicines have the characteristics of fewer side effects and milder medicinal properties, and are widely
used in children.
According to data from Minai.
com, before 2020, the market size of pediatric proprietary Chinese medicines in China's urban public hospitals, county-level public hospitals, urban community centers and township health centers (referred to as China's public medical institutions) has increased year after year, with double-digit
growth rates.
Affected by the epidemic in 2020, the pediatric proprietary Chinese medicine market has declined, and after the normalization of the epidemic in 2021, it began to warm up sharply, with a year-on-year increase of 47.
54%, and the sales scale in the first half of 2022 exceeded 4.
6 billion yuan, an increase of 6.
12% over the same period last year, and it is expected to return to the pre-epidemic level
in 2022.
From the perspective of treatment categories, pediatric proprietary Chinese medicines covered 7 treatment subcategories, focusing on pediatric cold medicine and pediatric cough expectorant medicine, accounting for 43% and 38%
of sales respectively.
Due to the low immunity of children, colds and coughs are more common in daily life, and the demand for medication is relatively large
.
2022H1 Distribution of terminal pediatric proprietary Chinese medicine treatment in China's public medical institutions
The dosage form of the drug is mainly powder/granule and solution, accounting for 52% and 36% of the sales respectively, these two dosage forms are in line with the physiological characteristics of children, it is more convenient to take, and it is also the dosage form
of children's drugs encouraged by the state at present.
From the perspective of manufacturer pattern, the top 5 manufacturers are Jichuan Pharmaceutical, Kangyuan Pharmaceutical, Guizhou Sanli Pharmaceutical, Hunan Hansen Pharmaceutical, and Lunan Houpu Pharmaceutical
.
Jichuan Pharmaceutical has been ranked first for many consecutive years, and its hegemonic position is difficult to shake; Kangyuan Pharmaceutical's market share has increased year by year, entering the top three for the first time in 2018, and rising one place in the first half of 2022
.
02, 13 exclusive proprietary Chinese medicines seized the TOP20, 8 brands of sales soared by more than 10%,
from the ranking of terminal pediatric proprietary Chinese medicine products in China's public medical institutions in the first half of 2022, the total market share of TOP20 products exceeded 70%, of which 11 products sold more than 100 million, Pediatric Soy Qingheat Granules led with more than 900 million yuan, and Jinzhen Oral Liquid followed closely with more than 400 million yuan , Throat Open Throat Spray (children's type) ranked third
with more than 300 million yuan.
2022H1 Top 20 products of pediatric proprietary Chinese medicine in China's public medical institutions
Note: With * is the recommended medication for the "Guidelines for Home Medicine Intervention for Patients with New Coronavirus Infection"; Less than 100 million yuan - representing
that the 20 proprietary Chinese medicines are all varieties of the national medical insurance catalogue (3 in Category A and 17 in Category B), involving three treatment subcategories: pediatric cough and expectorant drugs (10), pediatric cold drugs (6) and pediatric anorexia drugs (4); From the perspective of the number of manufacturers, 13 are exclusive varieties (including exclusive dosage forms).
7 recommended drugs for children's treatment plans for the newly released "Guidelines for Home Medicine Intervention for Patients with New Coronavirus Infection", including Pediatric Soy Qiao Qingfei Granules (Jichuan Pharmaceutical), Jinzhen Oral Liquid (Jiangsu Kangyuan Pharmaceutical), Throat Open Sword Spray (Children's Type) (Guizhou Sanli Pharmaceutical), Pediatric Accumulation Cough Suppression Oral Liquid (Lunan Houpu Pharmaceutical), Awakening Spleen and Raising Children Granules (Guizhou Jianxing Pharmaceutical), Pediatric Chai Gui antipyretic granules (non-exclusive) and Qingxuan cough granules (Suzhong Pharmaceutical).
9 of the top 20 brands have sold more than 100 million
.
From the perspective of ranking changes (2022H1 VS 2021), Jiangsu Kangyuan Pharmaceutical's Jinzhen oral liquid, Hainan Huluwa Pharmaceutical's pediatric pulmonary fever cough granules, Changchun People's Pharmaceutical's pediatric pulmonary cough granules, Sunflower Pharmaceutical (Xiangyang) Longzhong's children's Chai Gui antipyretic granules, Jianmin Yekai Thai medicine (Suizhou) children's Baotaikang granules, Rongchang Pharmaceutical (Zibo) pediatric asthma oral liquid and other rankings have all risen
.
2022H1 Among the top 20 brands of pediatric proprietary Chinese medicine in China's public medical institutions, the growth rate exceeds 10%.
Note: Less than 100 million yuan* represents
8 brands up more than 10%, of which Changchun People's Pharmaceutical's pediatric cough granules rose by more than 33%, rising 7 places in the ranking, from 16th in 2021 to 9th in 2022H1; The children's Baotaikang granules of Jianmin Yekai Thai Medicine (Suizhou) once again ranked TOP20, ranking 15th in 2022H1; Rongchang Pharmaceutical (Zibo) Pediatric Asthma Oral Liquid ranked TOP20 for the first time, and ranked 20th in 2022H1
.
03.
Favorable policies are frequent, Huluwa, Jianmin.
.
.
In
order to encourage domestic pharmaceutical companies to increase the R&D and production of children's drugs, a series of encouraging policies have been introduced at the national level in recent years from multiple dimensions such as R&D, review, production and sales, such as including children's drugs in priority review and approval, and the adjustment of the national medical insurance catalogue to give priority to children's drugs
.
According to incomplete statistics, at present, there are 30 new pediatric proprietary Chinese medicine drugs in China that are in the clinical application stage or above (excluding the new indications or populations of new drugs that have been marketed), involving Huluwa, Jichuan Pharmaceutical, Jianmin Pharmaceutical, Yiling Pharmaceutical, Yili Pharmaceutical and many other enterprises
.
From the perspective of dosage form, the new pediatric proprietary Chinese medicine drugs currently under research are mainly suitable for children, such as granules, oral liquids, and plasters, and the indications are mostly
common pediatric diseases such as colds, bronchitis and diarrhea.
Eight new pediatric proprietary Chinese medicines are expected to be launched, among which Jianmin Pharmaceutical's Pediatric Purple Shellfish Cough Syrup (Pediatric Xuan Lung Cough Syrup) has been submitted for marketing application, Beijing Oriental Yunjia's Pediatric Golden Cough Granules, Hainan Huluwa Pharmaceutical's Pediatric Chemical Accumulation Granules, Jichuan Pharmaceutical's Pediatric Soy Qiao Qinghot Syrup, and Hunan Academy of Traditional Chinese Medicine Wheezing Kang Oral Liquid are in phase III clinical trials
.
.
From the perspective of the enterprises involved, Jianmin Pharmaceutical, Huluwa Pharmaceutical, Suzhou Yusen New Medicine, etc.
all have 2 or more pediatric new Chinese medicine drugs in clinical practice
.
Among them, Jianmin Pharmaceutical and Huluwa Pharmaceutical are listed in the TOP20 of the terminal pediatric proprietary Chinese medicine manufacturers in China's public medical institutions, while Suzhou Yusen New Drug specializes in innovative Chinese medicine research and industrialization
.
all have 2 or more pediatric new Chinese medicine drugs in clinical practice
.
Among them, Jianmin Pharmaceutical and Huluwa Pharmaceutical are listed in the TOP20 of the terminal pediatric proprietary Chinese medicine manufacturers in China's public medical institutions, while Suzhou Yusen New Drug specializes in innovative Chinese medicine research and industrialization
.
Source: Minainet database, State Administration of Traditional Chinese Medicine, etc
.
Review data statistics as of December 9, if there are any omissions, welcome to correct!
.
Review data statistics as of December 9, if there are any omissions, welcome to correct!
